Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0008752
UniProt IDP01375
Primary gene name(s)TNF
Synonym gene name(s)TNFA, TNFSF2
Protein nameTumor necrosis factor
Protein functionCytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells, Treg function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1, PP1, which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective, PubMed:23396208. Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line, PubMed:22517918. {ECO:0000269|PubMed:16829952, ECO:0000269|PubMed:22517918, ECO:0000269|PubMed:23396208}.; FUNCTION: The TNF intracellular domain, ICD form induces IL12 production in dendritic cells. {ECO:0000269|PubMed:16829952}.
Subcellular locationCell membrane {ECO:0000269|PubMed:16829952};
Single-pass type II membrane protein {ECO:0000269|PubMed:16829952}.;
SUBCELLULAR LOCATION: Tumor necrosis factor, membrane form: Membrane;
Single-pass type II membrane protein.;
SUBCELLULAR LOCATION: Tumor necrosis factor, soluble form: Secreted.;
SUBCELLULAR LOCATION: C-domain 1: Secreted.;
SUBCELLULAR LOCATION: C-domain 2: Secreted.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P01375
Gene Ontology
(Biological Process)
Complete annatation
activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919];
activation of MAPK activity [GO:0000187];
activation of MAPKKK activity [GO:0000185];
cellular response to amino acid stimulus [GO:0071230];
cellular response to nicotine [GO:0071316];
cellular response to organic cyclic compound [GO:0071407];
chronic inflammatory response to antigenic stimulus [GO:0002439];
cortical actin cytoskeleton organization [GO:0030866];
death-inducing signaling complex assembly [GO:0071550];
defense response to Gram-positive bacterium [GO:0050830];
embryonic digestive tract development [GO:0048566];
epithelial cell proliferation involved in salivary gland morphogenesis [GO:0060664];
establishment of protein localization to plasma membrane [GO:0090002];
extracellular matrix organization [GO:0030198];
extrinsic apoptotic signaling pathway [GO:0097191];
extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625];
glucose metabolic process [GO:0006006];
humoral immune response [GO:0006959];
I-kappaB kinase/NF-kappaB signaling [GO:0007249];
inflammatory response [GO:0006954];
intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630];
JNK cascade [GO:0007254];
leukocyte tethering or rolling [GO:0050901];
lipopolysaccharide-mediated signaling pathway [GO:0031663];
MAPK cascade [GO:0000165];
necroptotic signaling pathway [GO:0097527];
negative regulation of alkaline phosphatase activity [GO:0010693];
negative regulation of bicellular tight junction assembly [GO:1903347];
negative regulation of branching involved in lung morphogenesis [GO:0061048];
negative regulation of cytokine secretion involved in immune response [GO:0002740];
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240];
negative regulation of fat cell differentiation [GO:0045599];
negative regulation of gene expression [GO:0010629];
negative regulation of glucose import [GO:0046325];
negative regulation of growth of symbiont in host [GO:0044130];
negative regulation of interleukin-6 production [GO:0032715];
negative regulation of lipid catabolic process [GO:0050995];
negative regulation of lipid storage [GO:0010888];
negative regulation of myoblast differentiation [GO:0045662];
negative regulation of myosin-light-chain-phosphatase activity [GO:0035509];
negative regulation of osteoblast differentiation [GO:0045668];
negative regulation of protein complex disassembly [GO:0043242];
negative regulation of transcription, DNA-templated [GO:0045892];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
negative regulation of viral genome replication [GO:0045071];
osteoclast differentiation [GO:0030316];
positive regulation of apoptotic process [GO:0043065];
positive regulation of blood microparticle formation [GO:2000334];
positive regulation of calcidiol 1-monooxygenase activity [GO:0060559];
positive regulation of cell adhesion [GO:0045785];
positive regulation of ceramide biosynthetic process [GO:2000304];
positive regulation of chemokine, C-X-C motif ligand 2 production [GO:2000343];
positive regulation of chemokine biosynthetic process [GO:0045080];
positive regulation of chemokine production [GO:0032722];
positive regulation of chronic inflammatory response to antigenic stimulus [GO:0002876];
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043280];
positive regulation of cytokine production [GO:0001819];
positive regulation of cytokine secretion [GO:0050715];
positive regulation of ERK1 and ERK2 cascade [GO:0070374];
positive regulation of fever generation [GO:0031622];
positive regulation of gene expression [GO:0010628];
positive regulation of hair follicle development [GO:0051798];
positive regulation of heterotypic cell-cell adhesion [GO:0034116];
positive regulation of humoral immune response mediated by circulating immunoglobulin [GO:0002925];
positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123];
positive regulation of interferon-gamma production [GO:0032729];
positive regulation of interleukin-6 production [GO:0032755];
positive regulation of interleukin-8 biosynthetic process [GO:0045416];
positive regulation of interleukin-8 production [GO:0032757];
positive regulation of JUN kinase activity [GO:0043507];
positive regulation of leukocyte adhesion to arterial endothelial cell [GO:1904999];
positive regulation of leukocyte adhesion to vascular endothelial cell [GO:1904996];
positive regulation of MAP kinase activity [GO:0043406];
positive regulation of membrane protein ectodomain proteolysis [GO:0051044];
positive regulation of mononuclear cell migration [GO:0071677];
positive regulation of NFAT protein import into nucleus [GO:0051533];
positive regulation of NF-kappaB import into nucleus [GO:0042346];
positive regulation of NF-kappaB transcription factor activity [GO:0051092];
positive regulation of NIK/NF-kappaB signaling [GO:1901224];
positive regulation of nitric oxide biosynthetic process [GO:0045429];
positive regulation of osteoclast differentiation [GO:0045672];
positive regulation of peptidyl-serine phosphorylation [GO:0033138];
positive regulation of phagocytosis [GO:0050766];
positive regulation of podosome assembly [GO:0071803];
positive regulation of programmed cell death [GO:0043068];
positive regulation of protein complex assembly [GO:0031334];
positive regulation of protein complex disassembly [GO:0043243];
positive regulation of protein kinase activity [GO:0045860];
positive regulation of protein kinase B signaling [GO:0051897];
positive regulation of protein localization to cell surface [GO:2000010];
positive regulation of protein phosphorylation [GO:0001934];
positive regulation of protein transport [GO:0051222];
positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091];
positive regulation of smooth muscle cell proliferation [GO:0048661];
positive regulation of superoxide dismutase activity [GO:1901671];
positive regulation of transcription, DNA-templated [GO:0045893];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
positive regulation of translational initiation by iron [GO:0045994];
positive regulation of vitamin D biosynthetic process [GO:0060557];
protein import into nucleus, translocation [GO:0000060];
protein kinase B signaling [GO:0043491];
receptor biosynthetic process [GO:0032800];
regulation of branching involved in salivary gland morphogenesis [GO:0060693];
regulation of establishment of endothelial barrier [GO:1903140];
regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043122];
regulation of immunoglobulin secretion [GO:0051023];
regulation of insulin secretion [GO:0050796];
regulation of tumor necrosis factor-mediated signaling pathway [GO:0010803];
response to glucocorticoid [GO:0051384];
response to salt stress [GO:0009651];
response to virus [GO:0009615];
sequestering of triglyceride [GO:0030730];
tumor necrosis factor-mediated signaling pathway [GO:0033209]
Gene Ontology
(Molecular Function)
Complete annatation
cytokine activity [GO:0005125];
identical protein binding [GO:0042802];
protease binding [GO:0002020];
transcription regulatory region DNA binding [GO:0044212];
tumor necrosis factor receptor binding [GO:0005164]
Gene Ontology
(Cellular Component)
Complete annatation
cell surface [GO:0009986];
external side of plasma membrane [GO:0009897];
extracellular region [GO:0005576];
extracellular space [GO:0005615];
integral component of plasma membrane [GO:0005887];
membrane raft [GO:0045121];
phagocytic cup [GO:0001891];
plasma membrane [GO:0005886];
recycling endosome [GO:0055037]
Protein-protein interaction112979
Phylogenetic treeP01375
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD33.2190094620572700
AZA vs. DISU-0.007020584892232120.9779564779893080.997889048290254
AZA vs. IL70.7933861292635144.48236198423713e-050.00866187720364182
AZA vs. SAHA0.3336622899456990.1971000915528310.564610415776014
DISU vs. CD3-3.238577511102382.22044604925031e-161.40634469522686e-14
DISU vs. IL70.7910283750848780.001854073068194070.040332108950975
DISU vs. SAHA0.3437322253850010.2412160348319280.620052338555686
DMSO vs. AZA0.03859587859384440.8198154223776921
DMSO vs. CD3-3.1914033717918900
DMSO vs. DISU0.04399800238474370.8574209390477620.983807945138555
DMSO vs. IL70.7620641806042232.75853455806718e-050.00452009874596335
DMSO vs. SAHA0.2901467541411220.2230215572874690.568147040209507
HIV vs. Mock in Activation-0.4989657703169120.4249623094256040.999983755607037
HIV vs. Mock in Latency0.5399867845202540.09613548595954270.999834320637052
IL7 vs. CD3-2.419479958580968.11906097908377e-132.39020715112753e-11
SAHA vs. CD3-2.908739116042062.95319324550292e-141.20936473396003e-12
SAHA vs. IL7-0.4614893916165160.06138270425843780.210148281624277
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock 0.832 5.47E-09 3.79E-07
Infected vs. Bystander 1.19 4.70E-12 7.87E-10
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
1.7 0.001688875 1.2 0.094624757 1.6 0.107999986
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 1.59076 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00005 Etanercept approved, investigational yes antibody
DB00051 Adalimumab approved yes antibody
DB00065 Infliximab approved yes inhibitor
DB01041 Thalidomide approved, investigational, withdrawn yes inhibitor
DB00608 Chloroquine approved, vet_approved unknown unknown
DB01296 Glucosamine approved unknown unknown
DB01407 Clenbuterol approved, vet_approved unknown other/unknown
DB01411 Pranlukast approved unknown other/unknown
DB01427 Amrinone approved unknown inhibitor
DB05207 SD118 investigational unknown unknown
DB05250 681323 investigational unknown unknown
DB05218 PN0621 investigational unknown unknown
DB05017 YSIL6 investigational unknown unknown
DB05303 OMS-103HP investigational unknown unknown
DB04956 Afelimomab investigational unknown unknown
DB05066 AV411 investigational unknown unknown
DB02325 Isopropyl Alcohol approved unknown unknown
DB05412 SCIO-469 investigational unknown unknown
DB05470 VX-702 investigational unknown unknown
DB05744 CRx-139 investigational unknown unknown
DB05767 HMPL-004 investigational unknown unknown
DB05758 CYT007-TNFQb investigational unknown unknown
DB05869 CTI-01 investigational unknown unknown
DB05879 AME-527 investigational unknown unknown
DB05676 Apremilast approved, investigational unknown unknown
DB08904 Certolizumab pegol approved yes neutralizer
DB08910 Pomalidomide approved yes inhibitor
DB06674 Golimumab approved yes antibody
DB00668 Epinephrine approved, vet_approved unknown antagonist
DB00852 Pseudoephedrine approved unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1A8M X-ray 2.3Å A/B/C=77-233.
1TNF X-ray 2.6Å A/B/C=77-233.
2AZ5 X-ray 2.1Å A/B/C/D=86-233.
2E7A X-ray 1.8Å A/B/C=77-233.
2TUN X-ray 3.1Å A/B/C/D/E/F=77-233.
2ZJC X-ray 2.5Å A/B/C=77-233.
2ZPX X-ray 2.8Å A/B/C=77-233.
3ALQ X-ray 3.0Å A/B/C/D/E/F=77-233.
3IT8 X-ray 2.8Å A/B/C/G/H/I=82-233.
3L9J X-ray 2.1Å T=85-233.
3WD5 X-ray 3.1Å A=77-233.
4G3Y X-ray 2.6Å C=77-233.
4TSV X-ray 1.8Å A=84-233.
4TWT X-ray 2.8Å A/B/C/D=77-233.
5TSW X-ray 2.5Å A/B/C/D/E/F=84-233.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 interacts with 1380260
1237298216313253
2259136122496218
22496218
8336118
186702169744279
matrix upregulates 12105273
1254249616427155
Nef inhibits 11153078
16109884
20068037
capsid upregulated by 24903666
24999042
capsid enhances 25240755
Envelope transmembrane glycoprotein gp41 inhibits 25121610
Envelope surface glycoprotein gp120 inhibits 22814248
Tat modulates 25613133
25613138
Envelope surface glycoprotein gp160; precursor induces release of 9226228
Tat cooperates with 24714696
Vpr inhibits 23001849
9449720
Nef induces cleavage of 23317503
Tat regulated by 15661163
17376903
Envelope surface glycoprotein gp120 upregulates 16621960
1918999
9223523
18670216
2416277422528837
23867815
24043886
25856395
7511078
7815507
8764000
9108403
9225992
9658081
12089333
15481145
161601888707350
12372982
17030448
20380698
Asp induces release of 25809376
Tat downregulates 16547255
21900165
Envelope surface glycoprotein gp120 enhances 22463742
8870842
matrix increases 26347747
Pr55(Gag) upregulated by 15748898
Envelope surface glycoprotein gp120 cooperates with 20083573
24714696
matrix modulates 21482826
Vpr modulates 9334723
10775602
15142381
15780175
15817944
20380698
Tat interacts with 10376933
16375755
1857467718336259
2460748124696476
7859743
91101469378998
Envelope surface glycoprotein gp160; precursor downregulates 1993354
7706435
9269777
9344703
251216109344703
Nef induces release of 24705461
25056899
Vpr cooperates with 23001849
Nef enhances 25620704
Vpr upregulates 12457980
17475642
Envelope surface glycoprotein gp120 induces release of 11602715
1703044816846840
17030448
1918997
7536422
7561697
7704970
8267288
8482849
8806809
12089333
15288392
15307952
15481145
16313253
18826950
20121167
20817073
22340390
22463742
23554973
24043886
2492081821948112
22340390
Tat synergizes with 10438928
2058810315246652
19479051
19941336
7523444
7693046
205881039269771
20588103
22463742
Tat upregulates 11730934
1279199
7494249
7526541
7695626
7818827
7859743
8724035
8852605
9110146
9278385
9378998
9651389
9670843
9730685
10843712
10964543
11751963
12482669
14550782
16375755
1871041517312171
18692180
18710415
19234184
19621989
20380698
2404486723190742
24073214
2594389425879536
7494249
7859743
8724035
9438495
17376917
18344999
18926711
18971284
22463742
248556487526541
7859743
9639071
9651389
11860474
16697675
17451964
18574677
20121167
21274647
24418364
256131339278385
9730685
10843712
11579140
12482669
Pr55(Gag) interacts with 24227857
24942586
Tat activated by 11689614
Nef disrupts 20299515
Nef activates 20068037
Asp upregulated by 22569184
Envelope surface glycoprotein gp120 downregulates 17360657
8381971
Nef interacts with 24227857
Envelope surface glycoprotein gp160; precursor inhibits 25121610
Tat induces release of 16539678
2427525422937208
24165011
24696476
Pr55(Gag) induces release of 18945465
Vpu inhibits 11278695
Pr55(Gag) upregulates 12105273
1254249622395607
24942586
capsid regulated by 25840914
Tat inhibits 11522182
22814248
Envelope surface glycoprotein gp120 activates 18649336
Envelope transmembrane glycoprotein gp41 increases 26347747
Vpr enhances 26401039
Nef upregulates 10388525
12574335
20380698
22407921
2552928310415019
11000208
16091223
17086054
2192207312370346
17077296
23554973
2537863612504564
15576488
1645471116445909
1645471119455469
21668366
21858117
21886773
22395607
Envelope transmembrane glycoprotein gp41 upregulates 10964543
1548758
1905933
7561697
7706435
10964543
23383108

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01523 Antifolate resistance - Homo sapiens (human)
hsa04010 MAPK signaling pathway - Homo sapiens (human)
hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human)
hsa04064 NF-kappa B signaling pathway - Homo sapiens (human)
hsa04071 Sphingolipid signaling pathway - Homo sapiens (human)
hsa04150 mTOR signaling pathway - Homo sapiens (human)
hsa04210 Apoptosis - Homo sapiens (human)
hsa04350 TGF-beta signaling pathway - Homo sapiens (human)
hsa04380 Osteoclast differentiation - Homo sapiens (human)
hsa04612 Antigen processing and presentation - Homo sapiens (human)
hsa04620 Toll-like receptor signaling pathway - Homo sapiens (human)
hsa04621 NOD-like receptor signaling pathway - Homo sapiens (human)
hsa04622 RIG-I-like receptor signaling pathway - Homo sapiens (human)
hsa04640 Hematopoietic cell lineage - Homo sapiens (human)
hsa04650 Natural killer cell mediated cytotoxicity - Homo sapiens (human)
hsa04657 IL-17 signaling pathway - Homo sapiens (human)
hsa04660 T cell receptor signaling pathway - Homo sapiens (human)
hsa04664 Fc epsilon RI signaling pathway - Homo sapiens (human)
hsa04668 TNF signaling pathway - Homo sapiens (human)
hsa04920 Adipocytokine signaling pathway - Homo sapiens (human)
hsa04930 Type II diabetes mellitus - Homo sapiens (human)
hsa04931 Insulin resistance - Homo sapiens (human)
hsa04932 Non-alcoholic fatty liver disease (NAFLD) - Homo sapiens (human)
hsa04933 AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human)
hsa04940 Type I diabetes mellitus - Homo sapiens (human)
hsa05010 Alzheimer's disease - Homo sapiens (human)
hsa05014 Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human)
hsa05133 Pertussis - Homo sapiens (human)
hsa05134 Legionellosis - Homo sapiens (human)
hsa05140 Leishmaniasis - Homo sapiens (human)
hsa05142 Chagas disease (American trypanosomiasis) - Homo sapiens (human)
hsa05143 African trypanosomiasis - Homo sapiens (human)
hsa05144 Malaria - Homo sapiens (human)
hsa05145 Toxoplasmosis - Homo sapiens (human)
hsa05146 Amoebiasis - Homo sapiens (human)
hsa05152 Tuberculosis - Homo sapiens (human)
hsa05160 Hepatitis C - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05164 Influenza A - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05205 Proteoglycans in cancer - Homo sapiens (human)
hsa05310 Asthma - Homo sapiens (human)
hsa05321 Inflammatory bowel disease (IBD) - Homo sapiens (human)
hsa05322 Systemic lupus erythematosus - Homo sapiens (human)
hsa05323 Rheumatoid arthritis - Homo sapiens (human)
hsa05330 Allograft rejection - Homo sapiens (human)
hsa05332 Graft-versus-host disease - Homo sapiens (human)
hsa05410 Hypertrophic cardiomyopathy (HCM) - Homo sapiens (human)
hsa05414 Dilated cardiomyopathy - Homo sapiens (human)
Menu